Host Species:	Goat
Concentration:	1 mg/ml (OD 1.35 / 280 nm)
Antigen:	Human albumin
Purification:	Affinity purified
Buffer:	75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity	Specifically binds to human albumin. Dilution for immunoblot & ELISA range: 1,000 to 80,000. Centrifuge before use.
Use:	The antibody can be used for detection of human albumin in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Human albumin constitutes around 55% of the protein present in the plasma of normal healthy individuals. It is a single polypeptide chain of 585 amino acids with a molecular weight of 66 kDa.

The functions of human serum albumin include maintaining oncotic pressure; binding substances or drugs; regulating endogenous substances, metabolism; plasma buffer; antioxidant function; maintaining microvascular integrity; anticoagulant effects; inflammatory/anti-inflammatory effects; cell-signaling process. (Nicholson et al., 2000; Evans, 2002) Albumin also has functions that may play a critical role and have a great impact on different types of diseases, including hypo-albumin aemia and peripheral oedema. (Caironi et al. 2009)

Caironi, Pietro, and Luciano Gattinoni. "The clinical use of albumin: the point of view of a specialist in intensive care. " Blood Tranfusion 7.4 (2009): 259-67.

Evans, T. W. "Review Article: Albumin as a Drug-biological Effects of Albumin Unrelated to Oncotic Pressure." Alimentary Pharmacology and Therapeutics 16 (2002): 6-11.

Nicholson, J. P., M. R. Wolmarans, and G. R. Park. "The Role of Albumin in Critical Illness." British Journal of Anaesthesia 85.4 (2000): 599-610.

Citations

 

[A01]	2007	Kiyota, Akifumi; Matsushita, Taku; Ueoka, Ryuichi (2007): Induction and high density culture of human hepatoblasts from fetal hepatocytes with suppressing transformation. In Biological & Pharmaceutical Bulletin 30 (12), pp. 2308–2311.
[A01]	2006	Clavant, Steven P.; Sastra, Steve A.; Osicka, Tanya M.; Comper, Wayne D. (2006): The analysis and characterisation of immuno-unreactive urinary albumin in healthy volunteers. In Clinical Biochemistry 39 (2), pp. 143–151. DOI: 10.1016/j.clinbiochem.2005.10.013.

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。